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MaBACKGROUND A lack of clarity exists about the role of complete coronary revascularization in patients presenting with
non–ST-segment elevation myocardial infarction.
OBJECTIVES The aim of our study was to compare long-term outcomes in terms of major adverse cardiovascular and
cerebrovascular events of 2 different complete coronary revascularization strategies in patients with non–ST-segment
elevation myocardial infarction and multivessel coronary artery disease: 1-stage percutaneous coronary intervention
(1S-PCI) during the index procedure versus multistage percutaneous coronary intervention (MS-PCI) complete coronary
revascularization during the index hospitalization.
METHODS In the SMILE (Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction Patients:
One Stage Versus Multistaged Percutaneous Coronary Intervention) trial, 584 patients were randomly assigned in a 1:1
manner to 1S-PCI or MS-PCI. The primary study endpoint was the incidence of major adverse cardiovascular and cere-
brovascular events, which were deﬁned as cardiac death, death, reinfarction, rehospitalization for unstable angina, repeat
coronary revascularization (target vessel revascularization), and stroke at 1 year.
RESULTS The occurrence of the primary endpoint was signiﬁcantly lower in the 1-stage group (1S-PCI: n ¼ 36
[13.63%] vs. MS-PCI: n ¼ 61 [23.19%]; hazard ratio [HR]: 0.549 [95% conﬁdence interval (CI): 0.363 to 0.828];
p ¼ 0.004). The 1-year rate of target vessel revascularization was signiﬁcantly higher in the MS-PCI group
(1S-PCI: n ¼ 22 [8.33%] vs. MS-PCI: n ¼ 40 [15.20%]; HR: 0.522 [95% CI: 0.310 to 0.878]; p ¼ 0.01; p
log-rank ¼ 0.013). When the analyses were limited to cardiac death (1S-PCI: n ¼ 9 [3.41%] vs. MS-PCI: n ¼ 14
[5.32%]; HR: 0.624 [95% CI: 0.270 to 1.441]; p ¼ 0.27) and myocardial infarction (1S-PCI: n ¼ 7 [2.65%] vs.
MS-PCI: n ¼ 10 [3.80%]; HR: 0.678 [95% CI: 0.156 to 2.657]; p ¼ 0.46), no signiﬁcant differences were
observed between groups.
CONCLUSIONS In multivessel non–ST-segment elevation myocardial infarction patients, complete 1-stage coro-
nary revascularization is superior to multistage PCI in terms of major adverse cardiovascular and cerebrovascular
events. (Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction [NSTEMI] Patients: One
Stage Versus Multistaged Percutaneous Coronary Intervention [PCI] [SMILE]: NCT01478984) (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
1S-PCI = 1-stage percutaneous
coronary intervention
ACS = acute coronary
syndrome
CI = conﬁdence interval
HR = hazard ratio
IQR = interquartile range
MACCE = major adverse
cardiovascular and
cerebrovascular event(s)
MS-PCI = multistage
percutaneous coronary
intervention
NSTEMI = non–ST-segment
elevation myocardial infarction
PCI = percutaneous coronary
intervention
TIMI = Thrombolysis In
Myocardial Infarction
TVR = target vessel
revascularization
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265P ercutaneous coronary intervention (PCI) is thetreatment of choice in patients with acute coro-nary syndromes (ACS). A lack of clarity exists
about the role of complete coronary revascularization
by PCI in patients with non–ST-segment elevation
myocardial infarction (NSTEMI) (1). American College
of Cardiology/American Heart Association and Euro-
pean Society of Cardiology guidelines are unclear as
to which coronary revascularization strategy to sug-
gest in multivessel NSTEMI patients (2,3). In this
setting, identiﬁcation of the culprit lesion by angiog-
raphy alone could be challenging. Moreover, as
suggested by histopathological, intravascular ultra-
sound, and optical coherence tomography analysis,
secondary plaque ruptures in patients with ACS are
frequent (about 25%) (4–10). Therefore, as observed
in clinical observational studies, routine PCI of noncul-
prit arteries in NSTEMI may be of beneﬁt (11–17). In
accordance with the superiority of complete revascu-
larization in multivessel patients, not much data exist
on the difference in clinical outcomes between 1-stage
percutaneous coronary intervention (1S-PCI) and
multistage percutaneous coronary intervention (MS-
PCI) complete coronary revascularization. The aim of
our studywas to compare long-term outcomes in terms
of major adverse cardiovascular and cerebrovascular
events (MACCE) of 2 different complete coronary
revascularization strategies in patients with NSTEMI
andmultivessel coronary artery disease: 1S-PCI during
the index procedure versus MS-PCI complete coronary
revascularization during the index hospitalization.SEE PAGE 273METHODS
STUDY POPULATION. This is a 2-center, unblinded,
randomized clinical trial (NCT01478984). From
September 1, 2011, to August 31, 2013, all consecutive
NSTEMI patients scheduled to undergo an early inva-
sive revascularization strategy (PCI within 24 h) were
recruited in 2 different centers. Five hundred and
forty-two patients were randomly assigned in a 1:1
manner to 1S-PCI or MS-PCI (Figure 1). In MS-PCI, the
second-stage procedure was performed between 3 and
7 days after the index procedure. The inclusion criteria
were the following: age $18 years; diagnosis of
NSTEMI according to current guidelines, presenting
with multivessel disease (3); glomerular ﬁltration rate
>60 ml/min; planned early invasive strategy; and
signed informed consent. Exclusion criteria were the
following: cardiogenic shock; chronic total occlusion;
previous coronary artery bypass graft surgery;
SYNTAX (Synergy Between PCI With Taxus and Car-
diac Surgery) score >32; candidate for bypass surgery;and severe valvular heart disease. The proto-
col was accepted by the institutional ethical
boards and was performed in accordance with
the Declaration of Helsinki. All patients pro-
vided written informed consent.
The institutional review board deﬁned
procedure success as the achievement of an
angiographic residual stenosis <30% and a
TIMI (Thrombolysis In Myocardial Infarction)
ﬂow grade 3 after PCI.
STUDY DESIGN. Eligible patients were
randomly allocated to receive 1-stage or
multistage treatment using block allocation
(block size ¼ 8). Treatment was assigned on
the basis of a 1:1 ratio.
TREATMENT. Patients randomized to 1S-PCI
were completely revascularized during the
index procedure, whereas patients random-
ized to MS-PCI underwent a culprit-only
revascularization during the index proce-
dure, followed by a deferred complete coro-
nary revascularization of nonculprit lesions
within 3 to 7 days (4.76  1.23 days) during the index
hospitalization. In the MS-PCI, the identiﬁcation of
the culprit vessel was performed according to clinical
and angiographic parameters. The use of anatomic
(intravascular ultrasound or optical coherence to-
mography) or functional (fractional ﬂow reserve)
imaging modalities to assess the culprit lesion or
the presence of signiﬁcant coronary stenoses was
left to the operator’s discretion. Radial access was
strongly suggested for performance of coronary
angiography and PCI. All patients were treated
according to good clinical practice and the standard
of care (18). Dual antiplatelet therapy was adminis-
tered according to current European Society of
Cardiology guidelines (18).
CLINICAL FOLLOW-UP. Telephone-based interviews
andofﬁce-baseddirect visitswere performed at 1, 6, and
12 months, respectively, for endpoint adjudication.
ENDPOINTS. Primary study endpoints were deﬁned
as the incidence of MACCE deﬁned as cardiac death,
death, reinfarction, rehospitalization for unstable
angina, repeat coronary revascularization (target
vessel revascularization [TVR]), and stroke at 1 year.
Periprocedural myocardial infarction was not consid-
ered a MACCE. Myocardial infarction was deﬁned as
symptoms of cardiac ischemia and a troponin level
above the 99th percentile value. For patients with a
recurrent myocardial infarction within 14 days after
randomization, the deﬁnition required new electro-
cardiographic evidence of ST-segment elevation, or
new onset of left bundle branch block, or ST-segment
FIGURE 1 SMILE Trial Flowchart
Between September 2011 and August 2013
1,091 pts with diagnosed NSTEMI
were scheduled.
615 multivessel pts
(56.3%)
542 pts randomized
476 pts excluded :
143 pts nonsuitable for early
invasive strategy according to 
GRACE risk score
30 pts previous CABG
303 pts with a single lesion
73 pts excluded :
5 pts left main coronary artery
disease,
55 Syntax score >32 and/or
indication to CABG revascularization
3 pts severe valvular heart disease
10 refused consent
Complete coronary
revascularization
Allocation
Follow-Up
1-stage PCI revascularization n = 264
MACCE at 12 months analyzed
Multistage PCI revascularization n = 263
MACCE at 12 months analyzed
Lost to follow-up:
n = 6
Lost to follow-up:
n =9
ITT analysis
Analyzed (n = 264)
Excluded from analysis (n = 0)
Analyzed (n = 263)
Excluded from analysis (n = 0)
Patients with GRACE (Global Registry of Acute Coronary Events) risk scores <100 were not selected for an early invasive strategy. CABG ¼
coronary artery bypass graft; ITT ¼ intention-to treat; MACCE ¼ major adverse cardiovascular and cerebrovascular event(s); NSTEMI ¼ non–
ST-segment myocardial infarction; PCI ¼ percutaneous coronary intervention; pts ¼ patients; SMILE ¼ Impact of Different Treatment in
Multivessel Non ST Elevation Myocardial Infarction Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention.
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266depression, or transient elevation and/or T-wave
changes and a rise of the troponin level above the
99th percentile, with a $20% increase of the troponin
value in the second sample and/or with angiographic
evidence of ACS (19). Unstable angina was deﬁned
as angina despite medical therapy, supported by
objective evidence of ischemia (electrocardiographic
changes during a spontaneous episode of pain at rest).
Stroke was deﬁned as permanent neurological deﬁcit
adjudicated by a neurologist and conﬁrmed by mag-
netic resonance imaging control. TVR was deﬁned
as any revascularization procedure, including by-
pass surgery, involving the initially treated artery.Bleeding was deﬁned according to the Academic
Research Consortium deﬁnition (20).
STATISTICAL ANALYSIS. In order to assess the supe-
riority of MS-PCI compared with 1S-PCI, we assumed
the incidence of MACCE to be 9% in the MS-PCI group
and 18% in the 1S-PCI group (21). On the basis of a
2-sided test size of 5% and a power of 80%, it was
calculated that a minimum of 247 patients would need
to be recruited in each group to detect a 9% difference
in the incidence of MACCE at 1 year. All analyses were
performed according to the intention-to-treat prin-
ciple and per-protocol analysis (Online Appendix).
All continuous variables were expressed as mean  SD
TABLE 1 Baseline Characteristics of the Studied Populations
1-Stage
(n ¼ 264)
Multistage
(n ¼ 263) p Value
Age, yrs 72 (6178) 73 (6278) 0.76
Sex 0.84
Male 207 (78.40) 209 (79.46)
Female 57 (21.60) 54 (20.54)
Medical history
Diabetes NID 90 (34.09) 93 (35.36) 0.78
Diabetes ID 8 (3.03) 11 (4.18) 0.49
Hypertension 193 (73.10) 174 (66.15) 0.09
Hypercholesterolemia 152 (57.57) 143 (54.37) 0.48
Current smoker 120 (45.45) 107 (40.68) 0.29
Family history 139 (52.65) 136 (51.71) 0.86
Previous MI 71 (26.89) 62 (23.57) 0.68
Previous PCI 41 (15.53) 44 (16.73) 0.72
Serum creatinine, mg/dl 0.9 (0.81.2) 0.9 (0.81.2) 0.78
Troponin,* ng/ml 0.50 (0.221.42) 0.46 (0.161.36) 0.38
GRACE death-
in-hospital
score
176 (156191) 175 (152188) 0.76
CRUSADE score 22 (1635) 23 (1736) 0.47
Systolic blood
pressure, mm Hg
130 (120140) 125 (115135) 0.46
Heart rate, beats/min 80 (6790) 78 (6588) 0.72
Left ventricular ejection
fraction, %
50 (4055) 50 (4055) 0.87
Values are median (interquartile range) or n (%). *Cutoff <0.014 ng/ml in both
centers.
CRUSADE ¼ Can Rapid risk stratiﬁcation of Unstable angina patients Suppress
ADverse outcomes with Early implementation of the ACC/AHA Guidelines;
GRACE ¼ Global Registry of Acute Coronary Events; ID ¼ insulin-dependent; MI ¼
myocardial infarction; NID ¼ noninsulin dependent; PCI ¼ percutaneous coronary
intervention.
TABLE 2 Procedural Characteristics According to
Randomized Allocation
1-Stage
(n ¼ 264)
Multistage
(n ¼ 263) p Value
Target vessels 0.25
Left anterior
descending
234 (37.6) 237 (38.5)
Right coronary
artery
155 (24.9) 159 (25.8)
Left circumﬂex 210 (33.7) 204 (33.2)
Left main 24 (3.8) 15 (2.4)
Treated vessels 2.36  0.45 2.34  0.8 0.71
Lesion type 0.52
A 87 (11.5) 76 (10.1)
B1 204 (27.0) 192 (25.6)
B2 192 (25.4) 193 (25.7)
C 272 (36.0) 289 (38.5)
Baseline angiographic
analysis
RVD, mm 2.90 (2.703.25) 2.90 (2.673.12) 0.46
Lesion length, mm 20.0 (13.532.5) 22.0 (14.034.0) 0.81
MLD, mm 0.32 (0.18 0.49) 0.27 (0.100.43) 0.43
Diameter stenosis, % 87.5 (79.095.0) 90.0 (85.097.0) 0.17
SYNTAX score 16 (1418) 15 (1418) 0.63
TIMI ﬂow pre-
procedure
3 (23) 3 (23) 0.78
FFR 65 (24.62) 71 (26.99) 0.55
OCT 31 (11.745) 42 (15.96) 0.17
IVUS 39 (14.77) 27 (10.26%) 0.16
Stents per patient 3 (24) 3 (24) 0.56
Stent type 0.55
Bare metal 137 (17.0) 141 (17.6)
Biolimus 300 (37.3) 302 (37.7)
Zotarolimus 45 (5.5) 46 (5.7)
Everolimus 316 (39.3) 305 (38.1)
POBA 6 (0.8) 7 (0.9)
Minimum stent
diameter, mm
3 (2.753.0) 3 (2.753.0) 0.56
Cumulative stent
length, mm
24 (1642) 24 (1642) 0.46
Access site 0.55
Femoral artery 44 (16.7) 39 (14.8)
Radial artery 220 (83.3) 224 (85.2)
Serum creatinine,*
mg/dl
1.0 (0.81.2) 1.1 (0.91.2) 0.46
Serum creatinine,†
mg/dl
0.9 (0.81.2) 1.0 (0.71.1) 0.65
Values are median (interquartile range), mean  SD, or n (%). *Measured 48 h
after index procedure. †Measured before discharge.
FFR ¼ fractional ﬂow reserve; IVUS ¼ intravascular ultrasound; MLD ¼minimum
luminal diameter; OCT ¼ optical coherence tomography; POBA ¼ plain old balloon
angioplasty; RVD ¼ reference vessel diameter; SYNTAX ¼ Synergy Between PCI
With Taxus and Cardiac Surgery; TIMI ¼ Thrombolysis In Myocardial Infarction.
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267and analyzed by the Student t test. Categorical vari-
ables with Gaussian distributions were analyzed by the
chi-square or Fisher exact test, as appropriate. Base-
line variables with non-Gaussian distributions were
compared using the Mann-Whitney U test and sum-
marized with medians and interquartile range (IQR).
For the primary endpoint and its components, 95%
conﬁdence intervals (CIs) are reported. The event-free
survival curve for MACCE was constructed using the
Kaplan-Meier method, and statistical differences be-
tween curves were assessed by the log-rank test. The
hazard ratio for treatment comparisons was estimated
using Cox proportional hazard models. Statistical
analysis was performed with SPSS (version 11.0, SPSS,
Chicago, Illinois). Clinical study endpoints were adju-
dicated by an independent endpoints committee
blinded to the randomization group.
RESULTS
A total of 542 patients were enrolled in the study
(15 patients were lost to follow-up), with 264 assigned
to the 1-stage complete coronary revascularizationgroup and 263 to the multistage complete coronary
revascularization group. The characteristics of the
patients at baseline were similar in the 2 groups
(Table 1), as were the use of drug-eluting stents, the
treated vessels, the completeness of revasculariza-
tion, and medical therapies at hospital discharge
(Table 2, Online Table 1).
FIGURE 2 Kaplan-Meier Curves of MACCE, TVR, Cardiac Death, and Death
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The Kaplan-Meier curves show the superiority of 1-stage complete coronary revascularization in terms of MACCE (A) and TVR (B). No signiﬁcant differences
were observed in terms of cardiac death (C) and death (D) between the 2 complete revascularization strategies. HR ¼ hazard ratio; MACCE ¼ major adverse
cardiovascular and cerebrovascular event(s); TVR ¼ target vessel revascularization.
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268According to Kaplan-Meier curves, the primary
endpoint was signiﬁcantly lower in the 1-stage group,
(p ¼ 0.004, log-rank test) (Figure 2). The 1-year pri-
mary outcome occurred signiﬁcantly more frequentlyin the MS-PCI group (1S-PCI: n ¼ 36 [13.63%] vs. MS-
PCI: n ¼ 61 [23.19%]; hazard ratio [HR]: 0.549 [95%
CI: 0.363 to 0.828]; p ¼ 0.004] (Table 3; the events
rate at 1 month and 6 months are reported in the
TABLE 3 1-Year Clinical Events According to Randomized Allocation
1-Stage
(n ¼ 264)
Multistage
(n ¼ 263)
Hazard Ratio
(95% CI) p Value
MACCE 36 (13.63) 61 (23.19) 0.549 (0.363–0.828) 0.004
Death 17 (6.43) 29 (11.02) 0.562 (0.309–1.023) 0.06
Cardiac death 9 (3.41) 14 (5.32) 0.624 (0.270–1.441) 0.27
Stroke 1 (0.38) 2 (0.76) 0.487 (0.044–5.368) 0.54
Myocardial infarction 7 (2.65) 10 (3.80) 0.678 (0.156–2.657) 0.46
STEMI 2 (0.76) 4 (1.52) 0.486 (0.089–2.654) 0.39
NSTEMI 5 (1.89) 6 (2.28) 0.812 (0.248–2.661) 0.73
UA needing hospitalization 11 (4.16) 13 (4.94) 0.797 (0.068–4.276) 0.68
TVR 22 (8.33) 40 (15.20) 0.522 (0.310–0.878) 0.01
Values are n (%) unless otherwise indicated. MACCE include cardiac death, death, reinfarction,
rehospitalization for unstable angina, repeat coronary revascularization (TVR), and stroke at
1 year.
CI ¼ conﬁdence interval; MACCE ¼ major adverse cardiovascular and cerebrovascular events;
NSTEMI ¼ non–ST-segment elevation myocardial infarction; STEMI ¼ ST-segment elevation
myocardial infarction, TVR ¼ target vessel coronary revascularization; UA ¼ unstable angina.
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269Online Tables 2 and 3). The 1-year rate of TVR was
signiﬁcantly higher in the MS-PCI group (1S-PCI: n ¼
22 [8.33%] vs. MS-PCI: n ¼ 40 [15.20%]; HR: 0.522
[95% CI: 0.310 to 0.878]; p ¼ 0.01; p log-rank ¼ 0.013)
(Online Table 4 reports the main characteristics of
patients who experienced TVR). A higher rate of
6-month stress test was observed in the MS-PCI group
during the follow-up period (1S-PCI: n ¼ 71 [26.89%]
vs. MS-PCI: n ¼ 93 (35.36); p ¼ 0.048). The analyses of
the 2 main components of the primary outcome,
cardiac death (1S-PCI: n ¼ 9 [3.41%] vs. MS-PCI: n ¼ 14
[5.32%]; HR: 0.624 [95% CI: 0.270 to 1.441]; p ¼ 0.27)
and myocardial infarction (1S-PCI: n ¼ 7 [2.65%]
vs. MS-PCI: n ¼ 10 [3.80%]; HR: 0.678 [95% CI: 0.156
to 2.657]; p ¼ 0.46), showed no signiﬁcant differences
between the groups (Figure 2, Table 3). The rate of
overall death did not differ signiﬁcantly between
the 2 study groups, but it presented a trend in favor of
1S-PCI (Figure 2, Table 3). No signiﬁcant differences
were observed between the 2 groups in terms of
stroke and rehospitalization for unstable angina
(Table 3), or in types 2, 3, 4, and 5 bleeding. However,
the 1-year rate of type 1 bleeding was signiﬁcantly
higher in the MS group (1S-PCI: n ¼ 2 [0.76%] vs. MS-
PCI: n ¼ 9 [3.42%]; HR: 0.528 [95% CI: 0.332 to 0.897];
p ¼ 0.03). No signiﬁcant differences in deﬁnite stent
thrombosis were observed (1S-PCI: n ¼ 1 [0.38%]
vs. MS-PCI: n ¼ 1 [0.38%]; HR: 0.437 [95% CI: 0.032
to 5.456]; p ¼ 1).
Radial access was performed with a rate of 84.2%,
with no differences between the groups (Table 2). In
the MS-PCI group, the rate of radial access during the
second procedure decreased to 64.6% (p < 0.001)
(Online Table 5) compared with 1S-PCI. Troponin T
values during the hospitalization decreased rapidly in
the 1S-PCI group, whereas a signiﬁcant increase of
troponin T was observed in the MS-PCI group
(median: MS-PCI baseline: [0.46 (IQR: 0.16, 1.36)]
vs. MS-PCI 12 h: [0.96 (IQR: 0.44, 1.76); p < 0.001).
Creatine kinase-myocardial band showed similar
kinetics to troponin (Online Table 6). No cases of
contrast-induced nephropathy requiring dialysis
were observed in the studied population (Online
Table 7). The per-protocol analysis is reported in the
Online Appendix.
DISCUSSION
The major ﬁndings of SMILE (Impact of Different
Treatment in Multivessel Non ST Elevation Myocar-
dial Infarction Patients: One Stage Versus Multistaged
Percutaneous Coronary Intervention) trial are as
follows: 1) 1-stage complete coronary revasculariza-
tion is superior to multistage complete coronaryrevascularization in terms of MACCE; 2) this is mainly
due to an unexplained higher incidence of TVR; 3) the
intention-to-treat analysis showed a net trend in
favor of 1S-PCI in terms of overall death; 4) the 1-stage
strategy, as compared with MS-PCI complete coronary
revascularization, is associated with a signiﬁcantly
lower incidence of minimal bleeding and a rapid
decrease in myocardial enzymes.
As previously reported, no randomized data exist
about the role of complete coronary revascularization
in NSTEMI patients. In this setting, guidelines are
also ambiguous and inconclusive (3–4). Recently
published Italian data reported on the treatment
of 43,645 multivessel patients, of whom 58.6%
(n ¼ 25,575) underwent complete coronary revascu-
larization in a single-stage procedure (22). Our hy-
pothesis was that a longer procedure duration, higher
contrast volume administered during the index pro-
cedure, a possible major rate of complications (peri-
procedural myocardial infarction, procedure-related
stroke, bleeding requiring transfusion, and contrast-
induced nephropathy requiring dialysis) could have
an impact on MACCE at long-term follow-up. How-
ever, our data showed the opposite results, mainly
due to a higher rate of TVR. A possible explanation for
this ﬁnding could be the observed higher rate of
6-month stress tests in the MS-PCI group during the
follow-up period (1S-PCI: n ¼ 71 [26.89%] vs. MS-PCI:
n ¼ 93 [35.36%]; p ¼ 0.0479). Cardiac enzyme levels
(in particular, troponin T), promptly decreased in the
1S-PCI group, whereas a signiﬁcant increase of
troponin T was observed in the MS-PCI group after
the index procedure (median: MS-PCI baseline [0.46
(IQR: 0.16 to 1.36)] vs. [0.96 (IQR: 0.44 to 1.76) 12 h;
p < 0.001); these results could be related to a longer
CENTRAL ILLUSTRATION Complete Coronary Revascularization Strategies in NSTEMI Patients with Multivessel Coronary Artery Disease
Sardella, G. et al. J Am Coll Cardiol. 2016; 67(3):264–72.
The SMILE (Impact of Different Treatment inMultivessel Non ST Elevation Myocardial Infarction Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention)
trial is a randomized study comparing 2 complete coronary revascularization strategies in patients presenting with non–ST-segment elevation myocardial infarction (NSTEMI)
and multivessel coronary artery disease. In the 1-stage percutaneous coronary intervention (PCI) group, complete coronary revascularization was performed during the index
procedure. In themultistagePCI group, culprit-only revascularizationwas performed during the index procedure and completed revascularizationwas achieved during a staged
procedure. The major ﬁnding of the study was that 1-stage PCI was superior to multistage PCI in terms of major adverse cardiovascular and cerebrovascular events (MACCE).
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: On the basis of near-term outcomes in patients with
NSTEMI and multivessel coronary artery disease, single-session
complete coronary interventional procedures are preferred over
multistage methods of percutaneous revascularization.
TRANSLATIONAL OUTLOOK: Longer-term follow-up studies
are needed to assess the comparative mortality beneﬁt of per-
forming complete coronary revascularization during index pro-
cedures, rather than delaying intervention on lesions in
nonculprit vessels in patients with NSTEMI.
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271time of ischemia in the MS-PCI. A longer time of
myocardial ischemia in MS-PCI group could be also
due to a possible erroneous identiﬁcation of the
culprit lesion during coronary angiography or to the
presence of multiple culprit lesions and, conse-
quently, to incomplete ischemia resolution (4–11).
Finally, in the MS-PCI group, a higher rate of minimal
bleeding was observed, probably due to a higher rate
of access site switching in the second procedure.
The SMILE trial is a randomized study that assumed
complete coronary revascularization as preferred
strategy in ACS multivessel patients. Comparing the
SMILE trial to previously published nonrandomized
studies is difﬁcult. Shishehbor et al. (12), in a pro-
spective propensity-matched analysis on 1,240 ACS
patients with multivessel coronary artery disease,
observed that complete coronary revascularization is
associated with a lower rate of the composite endpoint
(death, myocardial infarction, or revascularization).
If we compare the rate of MACCE in the SMILE
trial (1S-PCI: 13.63% vs. MS-PCI: 23.19%) with the
propensity-matched composite endpoint of Shisheh-
bor et al. (complete revascularization: 30.0% vs.
culprit-only strategy: 40.0%), a lower event rate was
observed, independent of the revascularization strat-
egy in complete revascularization (12). These results
suggest that complete coronary revascularization
should be the preferred strategy in multivessel pa-
tients, independent of the timing of revascularization.
In contrast, recently published data strongly sug-
gest that complete coronary revascularization is
associated with a signiﬁcant reduction in major
adverse cardiovascular events in the setting of STEMI
in multivessel patients (23–25).
STUDY LIMITATIONS. The SMILE trial had several
limitations: the primary endpoint is a combined one;
the trial is not powered for secondary endpoints; the
trial had an open-label design. Culprit-vessel-only
PCI was excluded as a possible revascularizationstrategy in our population. However, the mean
GRACE (Global Registry of Acute Coronary Events)
in-hospital score was >140, patients enrolled in the
study were at low risk, considering their SYNTAX
scores and preserved left ventricular ejection func-
tion. Fractional ﬂow reserve and other imaging
modalities were not routinely used to assess the
severity of coronary lesions.
CONCLUSIONS
In multivessel NSTEMI patients, 1S-PCI during
the index procedure is superior to MS-PCI complete
coronary revascularization during the index hospi-
talization in terms of MACCE (Central Illustration).
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